Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Janssen touts positive Tremfya and Stelara data for IBD at Digestive Disease Week

By Brian Buntz | May 25, 2022

Johnson & Johnson Janssen pharmaceutical business in the Pharma 50Johnson & Johnson’s (NYSE:JNJ) Janssen unit announced new Phase 2 GALAXI 1 data at Digestive Disease Week (DDW), showing substantial rates of clinical-biomarker and endoscopic response and clinical remission through 48 weeks of Tremfya (guselkumab) therapy for Crohn’s disease.

The company also announced long-term pooled safety analyses for Stelara (ustekinumab) at the DDW event May 21-24 in San Diego, California.

In the GALAXI 1 study focused on adults with moderately severe Crohn’s disease who were poor candidates for traditional therapies or biologics, guselkumab recipients had a clinical biomarker response between 47.5% and 66.7% at week 48 across dose groups. About 45% of such patients had an endoscopic response. In addition, between 39.3% and 66.7% achieved remission based on C-reactive protein (CRP) or fecal calprotectin levels in the same time interval.

At present, Tremfya is not FDA approved for Crohn’s disease or ulcerative colitis. It first won FDA approval for plaque psoriasis in 2017 and active psoriatic arthritis in 2020.

In addition, Janssen announced that Stelara has a positive safety profile in patients with inflammatory bowel disease based on pooled analyses of long-term safety data in bio-naïve and bio-failure Crohn’s disease and ulcerative colitis patients.

FDA approved the use of Stelara for Crohn’s disease in 2016 and for ulcerative colitis in 2019.

Outside of gastroenterology, the drug is approved for psoriasis, psoriatic arthritis and plaque psoriasis.

In a pooled safety analysis involving 13 studies across all approved indications, Stelara recipients had no increased incidence of malignancy compared to placebo.

That analysis pooled long-term safety data from 2,501 placebo recipients and 6,701 Stelara recipients for up to five years.

“These data provide validation and underscore our commitment to continuing to innovate for patients with disease where considerable need remains,” said Dr. Jan Wehkamp, vice president, gastroenterology disease area leader at Janssen Research & Development.


Filed Under: Gastroenterology
Tagged With: Crohn's disease, guselkumab, Janssen, Stelara, Tremfya, ulcerative colitis, ustekinumab
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

AbbVie
AbbVie’s Skyrizi becomes first drug to win FDA nod for Crohn’s disease
Bristol Myers Squibb
FDA approves new Opdivo indications for upper gastroesophageal cancers
AbbVie
AbbVie’s Rinvoq supports clinical remission in Phase 3 Crohn’s disease study
First Wave BioPharma
First Wave BioPharma stock tanks after announcing COVID-19 therapy trial data

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50